Stocktoria
InfuSystem Holdings, Inc INFU
InfuSystem Holdings, Inc (INFU) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $143.4M at a 4.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.3 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.161 |
| Retained earnings / assets | -0.604 |
| EBIT / assets | 0.119 |
| Equity / liabilities | 1.326 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INFU | InfuSystem Holdings, Inc | 8/9 | 1.27 | 30.1 | +6.4% |
| STIM | Neuronetics, Inc. | 4/9 | -10.38 | — | +99.2% |
| XTNT | Xtant Medical Holdings, Inc. | 8/9 | -3.66 | 12.7 | +14.2% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| HTFL | Heartflow, Inc. | 4/9 | -2.45 | — | +39.9% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
About InfuSystem Holdings, Inc
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
FAQ
Is INFU financially healthy?
InfuSystem Holdings, Inc's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does INFU pay a dividend?
No, InfuSystem Holdings, Inc does not currently pay a dividend.
How profitable is INFU?
In FY2025, InfuSystem Holdings, Inc had a net margin of 4.6% and a return on equity of 11.6%.
Is INFU overvalued or undervalued?
InfuSystem Holdings, Inc trades at about 39.5× trailing earnings — near its 10-year norm (10-year range 18.4×–251.7×, median 37.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for INFU?
The average Wall-Street price target for InfuSystem Holdings, Inc is $14.88, about 21.5% above the recent price, from 4 analysts.
Is INFU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on InfuSystem Holdings, Inc: a Piotroski F-score of 8/9, an Altman Z″ in the grey zone, a P/E of about 30.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.